Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

Blin-fant Study: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia: A collaborative study of the Interfant network

Leukaemia: Acute lymphoblastic leukaemia (MLL rearranged)

This study will investigate the effectiveness of the introduction of a new drug Blinotumomab to the standard treatment for infants diagnosed with acute lymphoblastic leukaemia (ALL). Blinotumomab attaches to the cancer cells, causing them to break down and die. Infants will be given the standard chemotherapy treatment for the first month, followed by an additional month of continuous treatment with Blinotumomab. This will require an extra period of hospitalisation.

Disease Stage: Newly diagnosed

Patient Age Range: < 1year

Sample Size: 30

Trial Sponsors:

  • International: Princess Maxima Center for Pediatric Oncology Netherlands
  • National: ANZCHOG

ANZCHOG acknowledges the valuable support of Blin-fant by Australian Government through Medical Research Future Fund.